Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Genitourinary 2Tumor-Agnostic 1Thoracic 1Endocrine 1Breast 1

Conditions

Prostatic Neoplasms 1Clear-cell metastatic renal cell carcinoma 1

Interventions

Docetaxel 390pembrolizumab 325Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Radiopharmaceuticals × Genitourinary × Clear all
NCT07567521 2026-05-29

A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC

C Ray Therapeutics

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Prostatic Neoplasms

NCT06059014 2026-04-24

PRadR

Centre Leon Berard

Phase 1/2 Completed
6 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡